UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December, 2023
Commission file number: 001-37891
AC IMMUNE SA
(Exact Name of Registrant as Specified in Its Charter)
EPFL Innovation Park
Building B
1015 Lausanne, Switzerland
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
On December 15, 2023, AC Immune SA (the “Company”) issued a press release announcing that its development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with preclinical AD, those individuals not yet showing symptoms. Under the terms of the licensing agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, the Company will now receive a milestone payment of CHF 15 million and is eligible to receive another milestone payment of CHF 25 million related to achieving a non-disclosed enrollment target. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 6-K.
This Report on Form 6-K (other than Exhibit 99.1 hereto) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File No. 333- 255576, File No. 333-227016 and File No. 333-249655) and Form S-8 (File No. 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | AC IMMUNE SA |
| | |
| | |
| | By: | /s/ Andrea Pfeifer |
| | | Name: Andrea Pfeifer |
| | | Title: Chief Executive Officer |
| | | |
| | | |
| | By: | /s/ Christopher Roberts |
| | | Name: Christopher Roberts |
| | | Title: Vice President, Finance and Interim Chief Financial Officer |
| | | |
| Date: December 15, 2023 | | |
